Eli Lilly Cuts Zepbound Prices by 50%
Eli Lilly Cuts Zepbound Prices by 50%

Eli Lilly Cuts Zepbound Prices by 50%

News summary

Eli Lilly has announced the launch of its weight-loss drug Zepbound in new 2.5 mg and 5 mg single-dose vials, significantly reducing the price to $399 and $549 per month, respectively, which is over 50% less than previous prices. The move aims to expand access to the drug for patients without insurance or those whose coverage does not include weight loss treatments. These vials differ from the previous auto-injector format, requiring patients to use a syringe for administration. The company emphasized that these changes will help meet the high demand and assist millions of adults with obesity. The announcement has impacted the stock prices of competitors in the weight-loss market, with shares of companies like Hims & Hers dropping in response. Eli Lilly's efforts come amid pressure from lawmakers to lower drug prices, highlighting the ongoing competitive dynamics in the obesity treatment sector.

Story Coverage
Bias Distribution
100% Left
Information Sources
bfb2a97b-336e-48d9-b69a-147df7862dc2
Left 100%
Coverage Details
Total News Sources
1
Left
1
Center
0
Right
0
Unrated
0
Last Updated
75 days ago
Bias Distribution
100% Left

Open Story Timeline

Story timeline 1Story timeline 2Story timeline 3Story timeline 4Story timeline 5Story timeline 6Story timeline 7Story timeline 8Story timeline 9Story timeline 10Story timeline 11Story timeline 12Story timeline 13Story timeline 14

Analyze and predict the
development of events

Related News
Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Related News
Recommended News